SLRN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SLRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Acelyrin's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Acelyrin's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .
Acelyrin's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Acelyrin's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .
Acelyrin's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Acelyrin's liquidation value for the three months ended in Mar. 2024 was $625.12 Mil.
The historical data trend for Acelyrin's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acelyrin Annual Data | |||||||
Trend | Dec21 | Dec22 | Dec23 | ||||
Change In Receivables | - | - | - |
Acelyrin Quarterly Data | ||||||||||
Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acelyrin (NAS:SLRN) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Acelyrin's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, Acelyrin's accounts receivable are only considered to be worth 75% of book value:
Acelyrin's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 678.538 | - | 53.417 | + | 0.75 * 0 | + | 0.5 * 0 |
= | 625.12 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Acelyrin's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Shao-lee Lin | director, officer: Chief Executive Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Gil M Labrucherie | officer: Interim CFO | 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
Beth C Seidenberg | director, 10 percent owner | |
Henry O Gosebruch | director | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092 |
Mardi Dier | officer: CFO and CBO | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Mina Kim | officer: Chief Legal & Admin. Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Ronald Oyston | officer: Chief People Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301 |
Paul Peloso | officer: Chief Medical Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301 |
Dawn Svoronos | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Daniel J. Becker | director | C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036 |
Westlake Biopartners Fund Ii, L.p. | 10 percent owner | 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361 |
Ayurmaya Capital Management Company, Lp | director, 10 percent owner, other: See Remarks | 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451 |
Sean E Harper | 10 percent owner | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Melanie Gloria | officer: Chief Operating Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301 |
Westlake Biopartners Gp Ii, Llc | 10 percent owner | 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361 |
From GuruFocus
By ACCESSWIRE • 01-05-2024
By PRNewswire • 12-28-2023
By PRNewswire • 12-30-2023
By PRNewswire • 12-18-2023
By PRNewswire • 01-02-2024
By PRNewswire • 12-18-2023
By PRNewswire • 01-05-2024
By PRNewswire • 01-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.